Skip to content
About
Science
Pipeline
News
Careers
Partnering
News
Press Releases
07/16/2026
Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity Treatment
Read More
Press Releases
06/09/2026
Syntis Bio Strengthens Leadership Team with Appointment of Matt Dallas as Chief Financial Officer
Read More
Press Releases
03/03/2026
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions
Read More
Press Releases
07/01/2025
Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
Read More
In The News
04/10/2025
WIRED Magazine: An Experimental Obesity Pill Mimics Gastric Bypass Surgery
Read More
Press Releases
04/10/2025
Syntis Bio Releases New Data Supporting Potential of SYNT-101 as a Once-Daily Oral Treatment for Obesity at European Congress on Obesity and Weight Management
Read More
Top
